Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Austar Lifesciences Ltd. ( (HK:6118) ) has issued an update.
Austar Lifesciences Ltd. announced its interim results for the six months ended June 30, 2025, showing a decrease in revenue from RMB 700,919,000 in 2024 to RMB 661,905,000 in 2025. Despite the revenue decline, the company reported a significant increase in profit before income tax, rising from RMB 9,186,000 in 2024 to RMB 30,303,000 in 2025, indicating improved operational efficiency. The profit attributable to the owners of the company also saw a substantial rise, reflecting a positive impact on the company’s financial health and potential benefits for stakeholders.
The most recent analyst rating on (HK:6118) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Austar Lifesciences Ltd. stock, see the HK:6118 Stock Forecast page.
More about Austar Lifesciences Ltd.
Austar Lifesciences Ltd. is a company incorporated in the Cayman Islands, operating in the lifesciences industry. It focuses on providing products and services related to the pharmaceutical and biopharmaceutical sectors.
Average Trading Volume: 1,446,466
Technical Sentiment Signal: Buy
Current Market Cap: HK$676.6M
For an in-depth examination of 6118 stock, go to TipRanks’ Overview page.